February 26, 2014
Wellesley, Mass., February 26, 2014 – According to a new technical market research report Histone Deacetylase Inhibitors: Emerging Markets, from BCC Research , the global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013. BCC Research expects the market to grow to $954.3 million by 2018, and register a five-year compound annual growth rate of 21.4% from 2013 to 2018.
Histone deacetylase inhibitors (HDIs) are promising therapeutics that have already shown potential for oncological applications such as cancer detection, diagnosis, and prognosis. Current candidates are demonstrating successful pre-clinical and clinical trials for various other diseases such as neurologogical ailments, heart diseases, HIV infections, and many others.
To date, there are just two approved HDIs -- vorinostat (Zolinza) from Merck & Co. and romidepsin (Istodax) from Celgene Corporation. Both of these are approved for cutaneous T-cell lymphoma (CTCL) and romidepsin is used for peripheral T-cell lymphoma (PTCL). Overall, the epigenetic drug market has four approved products of which two are vorinostat and romidepsin and other two are DNA methyl transferases (DNMT) Vidaza fom Celgene and Dacogen from Eisai pharmaceutical. This presents an enormous prospect for developing curative therapies for fatal diseases through histone deacetylase inhibitors. Consequently, global pharmaceutical and biopharmaceutical companies like Merck & Company, Novartis, Pfizer, and others are aiming to either discover new products or partner with smaller and midsized companies for their product development and commercialization.
The present market dynamics, including the prospective pipeline, collaborations and joint ventures, focused researches, and the growing need of drugs for fatal diseases such as cancer, neurodegenerative diseases, and others are driving the activities in the HDI space. There is enormous opportunity for this industry to develop and commercialize products for a huge patient base worldwide and this report presents the details meticulously.
This technical market research report from BCC Research provides an overview of the global HDIs market, including the progress of ongoing clinical developments of numerous candidates. The report portrays the present niche market for HDIs and projects a provisional picture of future market escalation derived from the current products, the impressive pipelines of histone deacetylase inhibitors, successful research and development activities, the strategic plans of larger biopharmaceuticals and pharmaceuticals, and the present and prospective market dynamics.
The report presents a holistic view on the present market size based on the two approved HDI products vorinostat (Zolinza) and romidepsin (Istodax). At the same time, it interprets the anticipated market size, revenue assessment, prospective products based on classical and second generation HDIs, market leaders, market shares, and drivers shaping the HDIs market. Market opportunities, restraints, patent analysis, new developments, and regulatory aspects are detailed to the extent of the scope of this report. Profiles of reputed as well as budding companies involved in the development of HDIs are also provided.
This report is intended for those with an interest in the histone deacetylase inhibitor market, including manufacturers/producers, researchers, research universities, other government and non-government organizations and like.
Histone Deacetylase Inhibitors: Emerging Markets( PHM163A )
Publish Date: Feb 2014
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.